April 14th 2025, 4:00pm
AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.
April 12th 2025, 2:00pm
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
April 11th 2025, 1:00pm
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 10th 2025, 8:00pm
I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.
April 4th 2025, 4:06pm
The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.
March 30th 2025, 6:00pm
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.
March 28th 2025, 3:00pm
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.
January 27th 2025, 2:00pm
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
January 23rd 2025, 4:00pm
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.
January 20th 2025, 2:00pm
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.
Aspiring to Make a Difference for Immigrants
Raising Awareness for Adolescents and Young Adults with Cancer
Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers
My 11-Year Metastatic Breast Cancer Story Defied the Standard Path